Ghost Tree Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Ghost Tree Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200,000	Closed	-$7.2M	–	67
2017 Q2	$7.2M	Sell	200,000 -100,000	-33%	-$3.2M	1.5%	25
2017 Q1	$9.24M	Buy	+300,000	New	+$9.34M	1.72%	22
2016 Q4	–	Sell	-250,000	Closed	-$6.65M	–	78
2016 Q3	$6.65M	Buy	+250,000	New	+$5.81M	1.08%	34
2014 Q4	–	Sell	-35,000	Closed	-$1.39M	–	70
2014 Q3	$1.39M	Sell	35,000 -15,000	-30%	-$598K	0.75%	49
2014 Q2	$2.15M	Buy	50,000 +15,000	+43%	+$572K	1.52%	24
2014 Q1	$1.4M	Buy	+35,000	New	+$1.27M	0.83%	44

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Ghost Tree Capital's ENTA Position: Q3 2017 in Review

Ghost Tree Capital sold out of Enanta Pharmaceuticals (ENTA) in Q3 2017, closing a stake of 200,000 shares — an estimated $7.2M sold.

Ghost Tree Capital first reported a position in ENTA in Q1 2014 and held it in 6 quarters. The position peaked at $9.24M in Q1 2017. 127 funds tracked by Wall St. Rank hold ENTA as of Q3 2017.

Ghost Tree Capital reported no remaining Enanta Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Ghost Tree Capital sold 200,000 Enanta Pharmaceuticals shares in Q3 2017, an estimated $7.2M.
Ghost Tree Capital first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Ghost Tree Capital's Enanta Pharmaceuticals position peaked at $9.24M in Q1 2017.
127 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2017.

Based on Ghost Tree Capital's 13F filing for Q3 2017, filed 14 Nov 2017.